• Natera will present new Signatera study results at the Society for Immunotherapy of Cancer meeting, Nov. 4-8 in Phoenix.
• The real-world analysis covered 424 patients receiving first-line immunotherapy across four metastatic cancer types.
• Patients with two consecutive negative Signatera tests had better long-term survival than other patients, with favorable outcomes across tumor types.
• Among these molecular responders, stopping immunotherapy early showed no significant survival difference compared with continuing treatment.
• The findings support further investigation of Signatera to identify patients who may safely stop immunotherapy early.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050700BIZWIRE_USPR_____20261105_BW562916) on November 05, 2026, and is solely responsible for the information contained therein.